Indeed, though CD47 blockade therapies have achieved early therapeutic efficacy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients in clinical trials (79, 80), this strategy has so far struggled in coping with solid tumors. Here, CD47 is linked to acute myeloid leukemia.